60 Degrees Pharmaceuticals (NASDAQ:SXTP) Issues Earnings Results

60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.14), FiscalAI reports. The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.27 million.

60 Degrees Pharmaceuticals Trading Down 6.2%

SXTP stock traded down $0.03 during trading on Monday, hitting $0.49. The company had a trading volume of 51,632 shares, compared to its average volume of 1,436,915. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.46 and a fifty-two week high of $8.62. The company has a market cap of $1.71 million, a P/E ratio of -0.10 and a beta of 2.47. The company has a fifty day moving average price of $0.94 and a two-hundred day moving average price of $1.65.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, 60 Degrees Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $13.85.

Read Our Latest Report on SXTP

60 Degrees Pharmaceuticals Company Profile

(Get Free Report)

60 Degrees Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for infectious diseases, particularly malaria and other parasitic infections. Its portfolio includes tafenoquine, an antimalarial medicine marketed in the United States as ARAKODA for the prevention of malaria in adults. The company is also studying tafenoquine for potential use against babesiosis, a tick-borne parasitic disease. These development programs are investigational; tafenoquine’s approval for malaria prevention does not extend to babesiosis.

Further Reading

Earnings History for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.